Evaluation  	Evaluation  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
interindividual  	interindividual  	 JJ	B-NP
human  	human  	 JJ	I-NP
variation  	variation  	 NN	I-NP
in  	in  	 IN	O
bioactivation  	bioactivation  	 NN	B-NP
of  	of  	 IN	I-NP
methyleugenol  	methyleugenol  	 NNS	I-NP
using  	using  	 VBG	O
physiologically  	physiologically  	 NNS	O
based  	based  	 VBN	O
kinetic  	kinetic  	 JJ	B-NP
modeling  	modeling  	 NN	I-NP
and  	and  	 CC	O
Monte  	Monte  	 NNP	B-NP
Carlo  	Carlo  	 NNP	I-NP
simulations  	simulations  	 VBD	I-NP
The  	The  	 DT	O
present  	present  	 JJ	O
study  	study  	 NN	O
aims  	aims  	 VBZ	O
at  	at  	 IN	O
predicting  	predicting  	 VBG	O
the  	the  	 DT	O
level  	level  	 NN	O
of  	of  	 IN	O
formation  	formation  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
ultimate  	ultimate  	 JJ	O
carcinogenic  	carcinogenic  	 JJ	B-NP
metabolite  	metabolite  	 NN	I-NP
of  	of  	 IN	I-NP
methyleugenol 	methyleugenol 	 NN	I-NP
,  	,  	 ,	O
1 	1 	 CD	O
' 	' 	 POS	B-NP
-sulfooxymethyleugenol 	-sulfooxymethyleugenol 	 JJ	I-NP
,  	,  	 ,	O
in  	in  	 IN	O
the  	the  	 DT	O
human  	human  	 JJ	O
population  	population  	 NN	O
by  	by  	 IN	O
taking  	taking  	 VBG	O
variability  	variability  	 NN	O
in  	in  	 IN	O
key  	key  	 JJ	B-NP
bioactivation  	bioactivation  	 NN	I-NP
and  	and  	 CC	O
detoxification  	detoxification  	 JJ	B-NP
reactions  	reactions  	 NNS	I-NP
into  	into  	 IN	O
account  	account  	 NN	O
using  	using  	 VBG	O
Monte  	Monte  	 NNP	B-NP
Carlo  	Carlo  	 NNP	I-NP
simulations 	simulations 	 NNS	I-NP
.  	.  	 .	O
Depending  	Depending  	 VBG	O
on  	on  	 IN	O
the  	the  	 DT	O
metabolic  	metabolic  	 JJ	B-NP
route 	route 	 NN	I-NP
,  	,  	 ,	O
variation  	variation  	 NN	O
was  	was  	 VBD	O
simulated  	simulated  	 VBN	O
based  	based  	 VBN	O
on  	on  	 IN	O
kinetic  	kinetic  	 NNS	B-NP
constants  	constants  	 VBP	I-NP
obtained  	obtained  	 VBN	O
from  	from  	 IN	O
incubations  	incubations  	 NN	O
with  	with  	 IN	O
a  	a  	 DT	O
range  	range  	 NN	O
of  	of  	 IN	O
individual  	individual  	 JJ	B-NP
human  	human  	 JJ	I-NP
liver  	liver  	 NN	I-NP
fractions  	fractions  	 NNS	I-NP
or  	or  	 CC	O
by  	by  	 IN	O
combining  	combining  	 VBG	O
kinetic  	kinetic  	 NNS	B-NP
constants  	constants  	 VBP	I-NP
obtained  	obtained  	 VBN	O
for  	for  	 IN	O
specific  	specific  	 JJ	O
isoenzymes  	isoenzymes  	 NN	B-NP
with  	with  	 IN	O
literature  	literature  	 NN	O
reported  	reported  	 VBD	O
human  	human  	 JJ	O
variation  	variation  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
activity  	activity  	 NN	O
of  	of  	 IN	O
these  	these  	 DT	O
enzymes 	enzymes 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
results  	results  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
study  	study  	 NN	O
indicate  	indicate  	 VBP	O
that  	that  	 DT	O
formation  	formation  	 NN	O
of  	of  	 IN	O
1 	1 	 CD	O
' 	' 	 POS	B-NP
-sulfooxymethyleugenol  	-sulfooxymethyleugenol  	 NN	I-NP
is  	is  	 VBZ	O
predominantly  	predominantly  	 RB	O
affected  	affected  	 VBN	O
by  	by  	 IN	O
variation  	variation  	 NN	O
in  	in  	 IN	O
i 	i 	 FW	O
)  	)  	 -RRB-	O
P450  	P450  	 CD	O
1A2-catalyzed  	1A2-catalyzed  	 CD	O
bioactivation  	bioactivation  	 NN	O
of  	of  	 IN	O
methyleugenol  	methyleugenol  	 VBG	O
to  	to  	 TO	O
1 	1 	 CD	O
' 	' 	 POS	B-NP
-hydroxymethyleugenol 	-hydroxymethyleugenol 	 JJ	I-NP
,  	,  	 ,	O
ii 	ii 	 CD	O
)  	)  	 -RRB-	O
P450  	P450  	 CD	O
2B6-catalyzed  	2B6-catalyzed  	 CD	O
epoxidation  	epoxidation  	 NN	O
of  	of  	 IN	O
methyleugenol 	methyleugenol 	 NN	B-NP
,  	,  	 ,	O
iii 	iii 	 CD	O
)  	)  	 -RRB-	O
the  	the  	 DT	O
apparent  	apparent  	 JJ	O
kinetic  	kinetic  	 JJ	B-NP
constants  	constants  	 NN	I-NP
for  	for  	 IN	O
oxidation  	oxidation  	 NN	O
of  	of  	 IN	O
1 	1 	 CD	O
' 	' 	 POS	B-NP
-hydroxymethyleugenol 	-hydroxymethyleugenol 	 JJ	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
iv 	iv 	 CD	O
)  	)  	 -RRB-	O
the  	the  	 DT	O
apparent  	apparent  	 JJ	O
kinetic  	kinetic  	 JJ	B-NP
constants  	constants  	 NN	I-NP
for  	for  	 IN	I-NP
sulfation  	sulfation  	 NN	I-NP
of  	of  	 IN	O
1 	1 	 CD	O
' 	' 	 POS	B-NP
-hydroxymethyleugenol 	-hydroxymethyleugenol 	 JJ	I-NP
.  	.  	 .	O
Based  	Based  	 VBN	O
on  	on  	 IN	O
the  	the  	 DT	O
Monte  	Monte  	 NNP	B-NP
Carlo  	Carlo  	 NNP	I-NP
simulations  	simulations  	 VBD	I-NP
a  	a  	 DT	O
so-called  	so-called  	 JJ	O
chemical-specific  	chemical-specific  	 JJ	B-NP
adjustment  	adjustment  	 NN	I-NP
factor  	factor  	 NN	I-NP
( 	( 	 -LRB-	O
CSAF 	CSAF 	 NNP	B-NP
)  	)  	 -RRB-	O
for  	for  	 IN	O
intraspecies  	intraspecies  	 JJ	B-NP
variation  	variation  	 NN	I-NP
could  	could  	 MD	O
be  	be  	 VB	O
derived  	derived  	 VBN	O
by  	by  	 IN	O
dividing  	dividing  	 VBG	O
different  	different  	 JJ	O
percentiles  	percentiles  	 NN	B-NP
by  	by  	 IN	O
the  	the  	 DT	O
50th  	50th  	 JJ	O
percentile  	percentile  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
predicted  	predicted  	 JJ	O
population  	population  	 NN	B-NP
distribution  	distribution  	 NN	I-NP
for  	for  	 IN	O
1 	1 	 CD	O
' 	' 	 POS	B-NP
-sulfooxymethyleugenol  	-sulfooxymethyleugenol  	 JJ	I-NP
formation 	formation 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
obtained  	obtained  	 VBN	B-NP
CSAF  	CSAF  	 NNP	I-NP
value  	value  	 NN	I-NP
at  	at  	 IN	O
the  	the  	 DT	O
90th  	90th  	 CD	O
percentile  	percentile  	 NNS	O
was  	was  	 VBD	O
3.2 	3.2 	 CD	O
,  	,  	 ,	O
indicating  	indicating  	 VBG	O
that  	that  	 IN	O
the  	the  	 DT	O
default  	default  	 NN	B-NP
uncertainty  	uncertainty  	 NN	I-NP
factor  	factor  	 NN	I-NP
of  	of  	 IN	O
3.16  	3.16  	 CD	O
for  	for  	 IN	O
human  	human  	 JJ	O
variability  	variability  	 NN	O
in  	in  	 IN	O
kinetics  	kinetics  	 NNS	O
may  	may  	 MD	O
adequately  	adequately  	 RB	O
cover  	cover  	 VB	O
the  	the  	 DT	O
variation  	variation  	 NN	O
within  	within  	 IN	O
90 	90 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
population 	population 	 NN	O
.  	.  	 .	O
Covering  	Covering  	 VBG	O
99 	99 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
population  	population  	 NN	O
requires  	requires  	 VBZ	O
a  	a  	 DT	O
larger  	larger  	 JJR	O
uncertainty  	uncertainty  	 NN	B-NP
factor  	factor  	 NN	I-NP
of  	of  	 IN	O
6.4 	6.4 	 CD	O
.  	.  	 .	O
In  	In  	 IN	O
conclusion 	conclusion 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
results  	results  	 NNS	O
showed  	showed  	 VBD	O
that  	that  	 DT	O
adequate  	adequate  	 JJ	O
predictions  	predictions  	 NNS	O
on  	on  	 IN	O
interindividual  	interindividual  	 JJ	B-NP
human  	human  	 JJ	I-NP
variation  	variation  	 NN	I-NP
can  	can  	 MD	O
be  	be  	 VB	O
made  	made  	 VBN	O
with  	with  	 IN	O
Monte  	Monte  	 NNP	O
Carlo-based  	Carlo-based  	 NNP	O
PBK  	PBK  	 NNP	B-NP
modeling 	modeling 	 NN	O
.  	.  	 .	O
For  	For  	 IN	O
methyleugenol  	methyleugenol  	 VBG	O
this  	this  	 DT	O
variation  	variation  	 NN	O
was  	was  	 VBD	O
observed  	observed  	 VBN	O
to  	to  	 TO	O
be  	be  	 VB	O
in  	in  	 IN	O
line  	line  	 NN	O
with  	with  	 IN	O
the  	the  	 DT	O
default  	default  	 NN	B-NP
variation  	variation  	 NN	I-NP
generally  	generally  	 RB	O
assumed  	assumed  	 VBN	O
in  	in  	 IN	O
risk  	risk  	 NN	B-NP
assessment 	assessment 	 NN	I-NP
.  	.  	 .	O
